Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines (BPMC)
NASDAQ:BPMC
BPMC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$80.42 - $121.90
Previous CloseN/A
Volume168.58K
Average Volume (3M)1.09M
Market Cap
$5.91B
Enterprise Value$5.86B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.75
Next Earnings
May 01, 2025EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding63,906,010
10 Day Avg. Volume1,301,492
30 Day Avg. Volume1,088,270
Standard Deviation0.14
R-Squared0.06
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.81
Price to Cash Flow (P/CF)-51.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.99
Enterprise Value/Ebitda-35.74
Forecast
1Y Price Target
$126.93Price Target Upside34.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
---
Blueprint Medicines News
---
Bulls Say, Bears Say
Bulls Say
Long-term Growth PotentialAyvakit can grow to $2B by 2030 as per management guidance with potential upside based on increased penetration in the increasingly prevalent SM population and other long-term growth drivers.
Market AdoptionThe company is observing incremental increases in Ayvakit use by dermatologists and gastroenterologists, indicating broader adoption beyond traditional allergy/immunology clinics.
Sales PerformanceAyvakit generated $144.1MM in sales revenue across all indications, with impressive growth figures including 12% quarter-over-quarter and 103% year-over-year growth.
Bears Say
Earnings GuidanceThe 2025 Ayvakit guidance was below investor expectations, contributing to an 8% drop in the stock price.
Price Target AdjustmentThe price target for the company has been lowered to $93 from $98, reflecting a more cautious outlook.
Revenue ExpectationsThe company's peak guidance for Ayvakit revenue has been revised downwards to $1.63bn from $1.68bn, indicating lower future expectations.
---
Ownership Overview
1.52% Insiders
42.04% Mutual Funds
26.65% Other Institutional Investors
12.27% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BPMC FAQ
What was Blueprint Medicines’s price range in the past 12 months?
Blueprint Medicines lowest stock price was $80.42 and its highest was $121.90 in the past 12 months.
What is Blueprint Medicines’s market cap?
Blueprint Medicines’s market cap is $5.91B.
When is Blueprint Medicines’s upcoming earnings report date?
Blueprint Medicines’s upcoming earnings report date is May 01, 2025 which is in 68 days.
How were Blueprint Medicines’s earnings last quarter?
Blueprint Medicines released its earnings results on Feb 13, 2025. The company reported -$0.79 earnings per share for the quarter, missing the consensus estimate of -$0.704 by -$0.086.
Is Blueprint Medicines overvalued?
According to Wall Street analysts Blueprint Medicines’s price is currently Undervalued.
Does Blueprint Medicines pay dividends?
Blueprint Medicines does not currently pay dividends.
What is Blueprint Medicines’s EPS estimate?
Blueprint Medicines’s EPS estimate is -0.45.
How many shares outstanding does Blueprint Medicines have?
Blueprint Medicines has 63,906,010 shares outstanding.
What happened to Blueprint Medicines’s price movement after its last earnings report?
Blueprint Medicines reported an EPS of -$0.79 in its last earnings report, missing expectations of -$0.704. Following the earnings report the stock price went down -8.082%.
Which hedge fund is a major shareholder of Blueprint Medicines?
Currently, no hedge funds are holding shares in BPMC
---
Blueprint Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$126.93 (34.53% Upside)
$126.93 (34.53% Upside)
Blogger Sentiment
Bullish
BPMC Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 12.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.39%
12-Months-Change
Fundamentals
Return on Equity
-31.26%
Trailing 12-Months
Asset Growth
12.44%
Trailing 12-Months
Company Description
Blueprint Medicines
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
---
BPMC Company Deck
---
BPMC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was predominantly positive, with strong revenue growth and market expansion for AYVAKIT, successful international progress, promising development of BLU-808, and financial discipline. However, some challenges in Q1 2025 and a heavy reliance on the U.S. market were noted.Read More>---
BPMC Stock 12 Month Forecast
Average Price Target
$126.93
▲(34.53% Upside)
Technical Analysis
Best Analysts Covering BPMC
1 Year
1 Year Success Rate
16/23 ratings generated profit
1 Year Average Return
+17.73%
reiterated a buy rating 9 days ago
Copying Marc Frahm's trades and holding each position for 1 Year would result in 69.57% of your transactions generating a profit, with an average return of +17.73% per trade.
---